Restricted accessOtherFirst published online 2009-11
Consideration of preanalytical impact of blood sampling on measurement of matrix metalloproteinases and their inhibitors as precondition to evaluate their relationship to clinical data
Benesová Y., Vasku A., Novotna H., et al. Matrix metalloproteinase-9 and matrix metalloproteinase-2 as bio-markers of various courses in multiple sclerosis . Mult Scler2009; 15: 316-322.
2.
Zucker S., Doshi K., Cao J.Measurement of matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMP) in blood and urine: potential clinical applications. Adv Clin Chem2004; 38: 37-85.
3.
Mannello F.Serum or plasma samples? The ‘‘Cinderella’’ role of blood collection procedures: preanalytical methodological issues influence the release and activity of circulating matrix metalloproteinases and their tissue inhibitors, hampering diagnostic trueness and leading to misinterpretation . Arterioscler Thromb Vasc Biol2008; 28: 611-614.
4.
Jung K., Klotzek S., Stephan C., Mannello F., Lein M.Impact of blood sampling on the circulating matrix metalloproteinases 1, 2, 3, 7, 8, and 9. Clin Chem2008; 54: 772-774.
5.
Mannello F., Jung K., Tonti GA, Canestrari F.Heparin affects matrix metalloproteinases and tissue inhibitors of metalloproteinases circulating in peripheral blood. Clin Biochem2008; 41: 1466-1473.
6.
Mannello F., Tonti GA, Canestrari F.The ‘neverending story’ of the influence of blood specimen collection methods affecting the concentration, the zymographic profile and the usefulness of matrix metalloproteinases and their tissue inhibitors in multiple sclerosis diagnosis/prognosis: a landmark for limiting the misuse of serum samples. Mult Scler2007; 13: 687-690.
7.
Mannello F., Tonti GAGelatinase concentrations and zymographic profiles in human breast cancer: matrix metalloproteinases circulating in plasma are better markers for the subclassification and early prediction of cancer: the coagulation/fibrinolysis pathways alter the release, activation and recovery of different gelatinases in serum. Int J Cancer2007; 121: 216-218.
8.
Makowski GS, Ramsby MLUse of citrate to minimize neutrophil matrix metalloproteinase-9 in human plasma. Anal Biochem2003; 322: 283-286.
9.
Meisser A., Cohen M., Bischof P.Concentrations of circulating gelatinases (matrix metalloproteinase-2 and -9) are dependent on the conditions of blood collection. Clin Chem2005; 51: 274-276.
10.
Gerlach RF, Uzuelli JA, Souza-Tarla CD, Tanus-Santos JEEffect of anticoagulants on the determination of plasma matrix metalloproteinase (MMP)-2 and MMP-9 activities. Anal Biochem2005; 344: 147-149.
